Open AccessODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity
Author(s) -
Marianne Klose,
Kim P. Huynh,
Kim Krogsgaard,
Jørgen Drejer,
Dr Pharm,
Sarah Byberg,
Sten Madsbad,
Faidon Magkos,
Senior Researcher,
Abdellatif Aharaz,
Berit Edsberg,
Jacob Tfelt,
Arne Astrup,
Ulla FeldtRasmussen
Publication year - 2022
Publication title -
journal of the endocrine society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.046
H-Index - 20
ISSN - 2472-1972
DOI - 10.1210/jendso/bvac150.1059
Subject(s) - medicine , placebo , waist , double blind , clinical endpoint , adverse effect , metoprolol , randomized controlled trial , clinical trial , anesthesia , obesity , surgery , pathology , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom